1. Home
  2. BGSF vs ACET Comparison

BGSF vs ACET Comparison

Compare BGSF & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

HOLD

Current Price

$6.07

Market Cap

63.4M

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$6.90

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGSF
ACET
Founded
2007
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.4M
69.6M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
BGSF
ACET
Price
$6.07
$6.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$9.00
$56.00
AVG Volume (30 Days)
24.1K
97.5K
Earning Date
03-11-2026
03-12-2026
Dividend Yield
32.36%
N/A
EPS Growth
67.37
N/A
EPS
N/A
N/A
Revenue
$272,499,000.00
N/A
Revenue This Year
$4.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.91
$0.45
52 Week High
$8.20
$9.05

Technical Indicators

Market Signals
Indicator
BGSF
ACET
Relative Strength Index (RSI) 54.39 44.63
Support Level $5.93 $6.54
Resistance Level $6.38 $8.34
Average True Range (ATR) 0.26 0.43
MACD -0.03 -0.07
Stochastic Oscillator 39.77 12.76

Price Performance

Historical Comparison
BGSF
ACET

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: